Evidence & regulatory context
- Mechanism
- No ChEMBL entity under 'benzyl quinolone carboxylic acid' or 'BQCA'. BQCA is a preclinical M1 muscarinic acetylcholine receptor positive allosteric modulator tool compound. No ClinicalTrials.gov record for BQCA itself. Clinical M1 PAM / M1-preferring agents exist as a class (e.g. SUVN-I6107 NCT06705088 phase 1; ANAVEX3-71 NCT06245213 phase 2) but are different chemical entities and were deliberately NOT recorded as trials for this entry.
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseTBIControlled cortical impactC57BL/6 (from MeSH indexing)Male (from MeSH indexing)Intraperitoneal5, 10 and 20 mg/kg
Model: Unilateral motorsensory cortical contusion injury, with sham injury controls
BQCA significantly improved spatial recall in the third week with minimal motor effects, modestly increased relative cerebral glucose uptake in motor regions and partially reversed lesion-related changes in hippocampal subregions, with no significant side effects at 20 mg/kg.
Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
